2023-04-18 14:00:00
Neurology: Janssen signs with Pipeline Therapeutics
The subsidiary of Johnson & Johnson (J&J) has just signed a license and development agreement with the Californian biotech Pipeline Therapeutics. This agreement relates to PIPE-307 intended for the treatment of disorders of the nervous system developed by Pipeline. Currently in phase I, this compound aims to restore myelin, the insulating sheath that surrounds the extensions of neurons.
According to the terms of the agreement, in exchange for the worldwide license for the R&D and commercialization of PIPE-307, the biotech will receive 50 million dollars (45.6 M€) in initial payment of Janssen, as well as a capital payment of $25 million. Ultimately, milestone payments are likely to reach $1bn. Pipeline will remain in charge of the development of the drug candidate within the framework of a phase II evaluating it in patients suffering from relapsing-remitting multiple sclerosis. “We are delighted to announce this agreement, which is in line with our vision to maximize the reach of PIPE-307 (…) In addition, we are pleased to strengthen our financial position thanks to the initial payment of this agreement”a souligné Carmine Stengone, p dg de Pipeline.
Diagnosis: BioMérieux launches a research partnership with Oxford Nanopore
BioMérieux continues to strengthen its R&D. The diagnostics specialist from Lyon has just entered into a research partnership with Oxford Nanopore Technologies. This British company is developing nanopore sequencing, a technology capable of analyzing long fragments of DNA or RNA. The objective of the collaboration is to achieve progress on the development of this technology for rapid diagnostic tests.
“Because it is scalable and provides real-time results, this unique technology is ideal for rapid, cost-effective characterization of pathogens in clinical specimens”, justifies bioMérieux in a press release. If the financial terms or the duration of the collaboration have not been specified, the first applications have been announced. BioMérieux and Oxford Nanopore will first work on a test to determine antibiotic resistance in the case of tuberculosis, on a test to identify pathogens in clinical samples as well as on the validation of the Oxford Nanopore sequencing platform with the bioMérieux EPISEQ CS application.
Smart Immune receives $5 million from the Bill & Melinda Gates Foundation
Smart Immune, specializing in the reconstitution of the immune system, has announced that it has received an investment of five million dollars from the Bill & Melinda Gates Foundation, which thus enters the capital of French biotech. With this funding, Smart Immune wishes to develop its platform called ProTcell, intended to bring out treatments for cancer and infectious diseases. The biotech also wants to move forward with a phase I/II clinical study evaluating its flagship drug candidate, Smart 101, on acute leukemia in adults.
“Our work to rearm the immune system of patients is particularly interesting for global public health issues because this concept might have applications beyond oncology, on infectious diseases such as HIV”, commented Karine Rossignol, CEO and co-founder of Smart Immune. Created in 2017, Smart Immune comes from the Imagine Institute of Genetic Diseases.
Selected for you
1681841996
#Janssen #Pipeline #Therapeutics #BioMérieux #Smart #Immune
